Cabaletta Bio Targets 1Q28 BLA Submission for Rese-cel

Manufacturing design decisions made at the outset of rese-cel's development are now shaping Cabaletta Bio's regulatory timeline, with a BLA submission targeted for Q1 2028 following anticipated RESET-Myositis registrational topline results in the second half of 2027. For CGT manufacturers and QA directors tracking how construct design and process standardization translate into submission readiness, the program offers a documented case study in safety-first development architecture.

CEO Steven Nichtberger cited deliberate choices around construct design, standard and well-characterized manufacturing, and weight-based dosing as central to rese-cel's benefit-risk profile. Enrollment in the registrational adult myositis cohort slowed during Q3 2026, which the company attributed to patient and physician caution following safety events reported by other CAR-T developers in the field. Screening and enrollment activity has since recovered, with multiple patients enrolled in recent weeks.

The planned BLA package will incorporate Phase 1/2 juvenile dermatomyositis data alongside the registrational adult cohort results, a combination the company believes positions rese-cel for Priority Review Voucher eligibility. Immunomodulator-free durability data from the complete Phase 1/2 dermatomyositis cohort at one year, and from the complete lupus nephritis cohort with follow-up extending to two years, are scheduled for presentation at ACR Convergence 2026, providing an early read on long-term immune reset sustainability.

A second registrational study, RESET-SSc, has been initiated in systemic sclerosis patients with interstitial lung disease, with endpoints evaluating lung function improvement and overall disease response. Systemic sclerosis carries one of the highest mortality rates among rheumatological conditions, and the inclusion of pulmonary endpoints signals a more complex efficacy measurement framework than the myositis program. In parallel, the preconditioning-free program is generating maturing data, with go-forward clinical development plans expected to be announced in the first half of 2027.

Cabaletta reported a cash position of $299.4 million as of September 30, 2026, extending operational runway into Q1 2028, aligned with the BLA submission target. For plant heads and regulatory affairs leads monitoring CGT pipeline timelines, the Q1 2028 filing date represents a near-term checkpoint against which manufacturing scale-up, process validation packages, and CMC documentation will need to be fully reconciled.

Source: Cabaletta Bio, Inc. via GlobeNewswire, November 5, 2026.